Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214590 | 1.00 | AKR1C3 (0.36) | AKR1C3RORCNR1H4KDM4ELMNA | |
| SCHEMBL213973 | 0.97 | AKR1C3 (0.36) | AKR1C3RORCNR1H4KDM4ELMNA | |
| SCHEMBL213974 | 0.97 | AKR1C3 (0.36) | AKR1C3RORCNR1H4KDM4ELMNA | |
| SCHEMBL215358 | 0.94 | AKR1C3 (0.38) | AKR1C3RORCKDM4ELMNA | |
| SCHEMBL215357 | 0.94 | AKR1C3 (0.38) | AKR1C3RORCKDM4ELMNA | |
| SCHEMBL216483 | 0.91 | KDM4E (0.37) | KDM4ELMNA | |
| SCHEMBL216482 | 0.91 | KDM4E (0.37) | KDM4ELMNA | |
| SCHEMBL215447 | 0.89 | AKR1C3 (0.40) | AKR1C3RORCKDM4ELMNA | |
| SCHEMBL215446 | 0.89 | AKR1C3 (0.40) | AKR1C3RORCKDM4ELMNA | |
| SCHEMBL216720 | 0.88 | NR1H4 (0.46) | RORCNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | claimed |
| US-7629369-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-12-08 | — | — | US | claimed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | claimed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| US-6503629-B2 | For forming a corrosion resistant coating film on steel, comprising a polyol-modified, amino group-containing epoxy resin modified with caprolactone | KANSAI PAINT CO., LTD. (JP) | 2003-01-07 | — | — | US | claimed |
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100041708-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20030161025-A1 | Electrochromic device | NIPPON OIL CORPORATION | 2003-08-28 | — | — | US | disclosed |
| US-6538792-B1 | Electrochromic devices which are useful as light controllable windows for buildings, automobiles, and various types of light controllable glasses to be used for indoor decoration or partitions; display devices; and antiglare mirrors | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2003-03-25 | — | — | US | disclosed |
| US-6532098-B1 | Sandwiched between two electrically conductive substrates at least one of which is transparent; benzidine or phenylenediamine compounds, acryloyl-modified polyalkylene oxide; viologen compound | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2003-03-11 | — | — | US | disclosed |
| US-6425792-B1 | Method for producing an electrochromic device | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2002-07-30 | — | — | US | disclosed |
| US-20020015214-A1 | Electrochromic Device | NIPPON MITSUBISHI OIL CORPORATION | 2002-02-07 | — | — | US | disclosed |
| US-6208452-B1 | HAS AN ION CONDUCTIVE LAYER OBTAINED BY CURING A COMPOSITION COMPRISING A BIPYRIDINIUM COMPOUND, A SPECIFIC AMINE COMPOUND AND A PRECURSOR COMPONENT OF A POLYMERIC SOLID ELECTROLYTE DISPOSED BETWEEN TWO ELECTRICALLY CONDUCTIVE SUBSTRATES | NIPPON MITSUBISHI OIL CORPORATION (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6023364-A | MULTILAYER; REFLECTIVE ELECTROCONDUCTIVE SUBSTRATE, TRANSPARENT LAYER, ELECTROCHROMIC CHROMOGENIC COMPOUND, SOLID ELECTROLYTES | NIPPON OIL CO., LTD. (JP) | 2000-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | AKR1C3 475/4885RORC 2228/4885NR1H4 2127/4885 |
| US-20100041708-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION | PTGER1, PTGER2, PTGES | AKR1C3 230/4885RORC 2534/4885NR1H4 1821/4885 |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | AKR1C3 323/4885RORC 4495/4885NR1H4 1549/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | AKR1C3 413/4885RORC 2507/4885NR1H4 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.